Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 838 participants.
Also called NCT02278341
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 838 participants
- Registry
-
NCT02278341 -
2013-001497-16
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Belgium, Bulgaria, Croatia, Czechia, France, Georgia, Germany, Hungary, Italy, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02278341. Randomized; no masking; primary purpose treatment. Start 2014-11-21 (actual); primary completion 2017-06-08 (actual). Results posted on 2020-08-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
- Acronym
- Pyrenees
- Condition
- Anemia
- Condition
- End Stage Renal Disease (ESRD)
- Intervention (Drug)
- Roxadustat
- Intervention (Drug)
- Epoetin alfa
- Intervention (Drug)
- Darbepoetin alfa
- Intervention (Drug)
- Iron
- Lead sponsor
- Astellas Pharma Europe B.V.
- Collaborator
- Kyntra Bio
Record details
- Record id
cardio:ct-nct02278341- Content hash
f3b8781394191346d4166a030c1089d140ed90deea44fc56a406070f615f62ce